Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Guillain-Barré syndrome in children: Treatment and prognosis

Monique M Ryan, FRACP
Section Editors
Douglas R Nordli, Jr, MD
Adrienne G Randolph, MD, MSc
Jeremy M Shefner, MD, PhD
Deputy Editor
John F Dashe, MD, PhD


The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barré syndrome (GBS). Typically, GBS presents as an acute monophasic paralyzing illness provoked by a preceding infection. The main modalities of therapy for GBS are intravenous immune globulin and plasma exchange. Even before initiating therapy, common questions that arise include whether the patient needs intensive care, assisted ventilation, or other supportive measures.

This topic will discuss the management and prognosis of GBS in children. Other aspects of GBS in children are discussed separately. (See "Guillain-Barré syndrome: Pathogenesis" and "Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis".)


The clinical features and diagnosis of GBS are reviewed here briefly and discussed in detail separately. (See "Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis".)

Acute inflammatory demyelinating polyneuropathy (AIDP) is the prototype of GBS, and is the most common form in North America, Europe and most of the developed world. Acute motor axonal neuropathy (AMAN) is a pure motor form of GBS. It occurs mainly in northern China, but is also a common variant of GBS in other locations, including Japan, Mexico, and South America. The clinical presentation is similar in the two types. In most cases, neurologic symptoms develop two to four weeks after what initially appears to be a benign febrile respiratory or gastrointestinal infection. The predominant symptoms of GBS at presentation in children are pain and gait difficulty. Lower extremity symmetric weakness may ascend over hours to days to involve the arms, and the muscles of respiration in severe cases. In those with cranial neuropathy, the facial nerve is most commonly affected, resulting in bilateral facial weakness. Autonomic dysfunction occurs in approximately one-half of children with GBS. Physical examination reveals symmetric weakness with diminished or absent reflexes. Most patients reach the nadir of their function within two to four weeks, followed by a slow return of function over the course of weeks to months. (See "Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis", section on 'Clinical features'.)

Electrophysiologic studies are the most specific and sensitive tests for diagnosis of GBS. Characteristic findings from lumbar puncture include a normal opening pressure and cerebrospinal fluid with fewer than 10 cells (typically mononuclear) and an elevated protein concentration (>45 mg/dL). Spinal MRI with administration of gadolinium frequently shows enhancement of the spinal nerve roots and cauda equina during the first weeks after the onset of symptoms. (See "Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis", section on 'Diagnosis'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 25, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barré syndrome. Arch Dis Child Educ Pract Ed 2007; 92:161.
  2. Evans OB, Vedanarayanan V. Guillain-Barré syndrome. Pediatr Rev 1997; 18:10.
  3. Hu MH, Chen CM, Lin KL, et al. Risk factors of respiratory failure in children with Guillain-Barré syndrome. Pediatr Neonatol 2012; 53:295.
  4. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62:1194.
  5. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58:893.
  6. Hund EF, Borel CO, Cornblath DR, et al. Intensive management and treatment of severe Guillain-Barré syndrome. Crit Care Med 1993; 21:433.
  7. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61:736.
  8. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.
  9. Hughes RA. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1991; 338:1142.
  10. Korinthenberg R, Mönting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 1996; 74:281.
  11. Gürses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 1995; 27:241.
  12. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005; 116:8.
  13. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; :CD002063.
  14. Kanra G, Ozon A, Vajsar J, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol 1997; 1:7.
  15. Shahar E, Shorer Z, Roifman CM, et al. Immune globulins are effective in severe pediatric Guillain-Barré syndrome. Pediatr Neurol 1997; 16:32.
  16. Singhi SC, Jayshree M, Singhi P, et al. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome. Ann Trop Paediatr 1999; 19:167.
  17. Shahar E, Leiderman M. Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy. Clin Neuropharmacol 2003; 26:84.
  18. Yata J, Nihei K, Ohya T, et al. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children. Pediatr Int 2003; 45:543.
  19. Irani DN, Cornblath DR, Chaudhry V, et al. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43:872.
  20. Castro LH, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43:1034.
  21. Koul R, Chacko A, Ahmed R, et al. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras. J Child Neurol 2003; 18:767.
  22. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009; 66:597.
  23. Farcas P, Avnun L, Frisher S, et al. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997; 350:1747.
  24. Second IVIg Dose in GBS patients with poor prognosis (SID-GBS trial). https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005659-83/NL/ (Accessed on August 29, 2016).
  25. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012; :CD001798.
  26. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990; 28:65.
  27. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care 2011; 15:R164.
  28. Bradshaw DY, Jones HR Jr. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992; 15:500.
  29. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007; 38:10.
  30. Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4.
  31. Delanoe C, Sebire G, Landrieu P, et al. Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies. Ann Neurol 1998; 44:350.
  32. Hung PL, Chang WN, Huang LT, et al. A clinical and electrophysiologic survey of childhood Guillain-Barré syndrome. Pediatr Neurol 2004; 30:86.
  33. Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol 2000; 15:183.
  34. Roodbol J, de Wit MC, Aarsen FK, et al. Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst 2014; 19:121.
  35. Nagasawa K, Kuwabara S, Misawa S, et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barré syndrome in Japan. Muscle Nerve 2006; 33:766.
  36. Barzegar M, Toopchizadeh V, Maher MHK, et al. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. Pediatr Res 2017; 82:333.
  37. Cole GF, Matthew DJ. Prognosis in severe Guillain-Barré syndrome. Arch Dis Child 1987; 62:288.
  38. Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr 2003; 142:305.
  39. Lin JJ, Hsia SH, Wang HS, et al. Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 2012; 47:91.
  40. Tekgul H, Serdaroglu G, Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barré syndrome in children. Pediatr Neurol 2003; 28:295.